The CO FIX that was investigated had similar specific activity levels to the WT protein (Fig. 4a); however, a lower concentration of hemophilia B serum, with anti-FIX antibodies, was required to inhibit its activity by 50%, compared to the WT FIX (Fig. 4b). The gene discussed is F9; the disease is hemophilia B.